Investors & Media

Investors & Media

Welcome to our investor page

We aspire to individualize cancer medicine

BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. To translate this idea into reality, we have combined ground-breaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and beyond. As we prove the value of our approach in the clinic, we will continue to build the partnerships, manufacturing and team required to bring individualized treatments to patients worldwide. From our roots in Mainz, Germany, we are driven to become the leading global biotechnology company for individualized cancer medicine.


Press Releases

25 November 2020

BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation ..

25 November 2020

BioNTech and Fosun Pharma Announce the Start of a Phase 2 Clinical Trial of Lea..

20 November 2020

Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the ..

Press releases (more)

Upcoming Events

November 30 - December 4, 2020

Berenberg European Conference 2020

Upcoming events (more)

Stock Quote

Nov 28, 2020 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.